t2dm sdf1 neutralising antibody Search Results


t2dm sdf1 neutralising antibody  (R&D Systems)
94
R&D Systems t2dm sdf1 neutralising antibody
FIGURE 2 | SDF-1 expression and release increase in PA-treated hepatocytes. The hepatocytes were divided into normal and PA (0.5 mmol/L for 24 h) groups. (A) <t>SDF1</t> protein levels in hepatocytes were detected by Western blot. (B) SDF-1 relative protein levels were analysed. (C) SDF-1 protein levels in hepatocyte culture supernatant were measured by ELISA. **p < 0.01, ***p < 0.001 versus normal group.
T2dm Sdf1 Neutralising Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t2dm+sdf1+neutralising+antibody/Human%2FMouse+CXCL12%2FSDF-1+Antibody/pm39855896-37-7-13
Average 94 stars, based on 1 article reviews
t2dm sdf1 neutralising antibody - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
human/mouse cxcl12/sdf-1 antibody  (Bio-Techne corporation)
96
Bio-Techne corporation human/mouse cxcl12/sdf-1 antibody
FIGURE 2 | SDF-1 expression and release increase in PA-treated hepatocytes. The hepatocytes were divided into normal and PA (0.5 mmol/L for 24 h) groups. (A) <t>SDF1</t> protein levels in hepatocytes were detected by Western blot. (B) SDF-1 relative protein levels were analysed. (C) SDF-1 protein levels in hepatocyte culture supernatant were measured by ELISA. **p < 0.01, ***p < 0.001 versus normal group.
Human/Mouse Cxcl12/Sdf 1 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t2dm+sdf1+neutralising+antibody/Human%2FMouse+CXCL12%2FSDF-1+Antibody/custom%40mab310%4039855896
Average 96 stars, based on 1 article reviews
human/mouse cxcl12/sdf-1 antibody - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

Image Search Results


FIGURE 2 | SDF-1 expression and release increase in PA-treated hepatocytes. The hepatocytes were divided into normal and PA (0.5 mmol/L for 24 h) groups. (A) SDF1 protein levels in hepatocytes were detected by Western blot. (B) SDF-1 relative protein levels were analysed. (C) SDF-1 protein levels in hepatocyte culture supernatant were measured by ELISA. **p < 0.01, ***p < 0.001 versus normal group.

Journal: Journal of cellular and molecular medicine

Article Title: Stromal Cell Derived Factor-1 Promotes Hepatic Insulin Resistance via Inhibiting Hepatocyte Lipophagy.

doi: 10.1111/jcmm.70352

Figure Lengend Snippet: FIGURE 2 | SDF-1 expression and release increase in PA-treated hepatocytes. The hepatocytes were divided into normal and PA (0.5 mmol/L for 24 h) groups. (A) SDF1 protein levels in hepatocytes were detected by Western blot. (B) SDF-1 relative protein levels were analysed. (C) SDF-1 protein levels in hepatocyte culture supernatant were measured by ELISA. **p < 0.01, ***p < 0.001 versus normal group.

Article Snippet: The mice were assigned into normal, T2DM, T2DM + SDF1 neutralising antibody (MAB310, R&D Systems, USA; 1 mg/kg/day, intrahepatic injection), T2DM + SDF1 neutralising antibody +3- Methyladenine (3- MA; autophagy inhibitor; HY- 19312, MedChemExpress, USA; 30 mg/kg/day, intrahepatic injection), T2DM + metformin (MET; S5958, Selleck, USA; 250 mg/kg/day, once a day from week 4 to week 6 of HFHSD feeding, oral administration) groups.

Techniques: Expressing, Western Blot, Enzyme-linked Immunosorbent Assay

FIGURE 5 | SDF-1 inhibits lipophagy in PA-treated hepatocytes via CXCR4, rather than CXCR7. The hepatocytes were divided into normal, PA, PA + SDF-1 neutralising antibody (1 μg for 24 h), PA + AMD3100 (10 μM for 24 h), and PA + ACT-1004-1239 (6 nM for 24 h) groups. (A) LC3, p62 and ATG7 protein levels in hepatocytes were detected by Western blot. (B–D) LC3, p62 and ATG7 relative protein levels were analysed. (E) The co- localization of the autolysosome (red) and the LD (green) in hepatocytes, indicated the induction of lipophagy (yellow). (F) The co-localization of autolysosome and LD was analysed. (G) The LD inside the hepatocytes was visualised by oil red O staining. **p < 0.01, ***p < 0.001 versus normal group. #p < 0.05, ##p < 0.01 versus PA group.

Journal: Journal of cellular and molecular medicine

Article Title: Stromal Cell Derived Factor-1 Promotes Hepatic Insulin Resistance via Inhibiting Hepatocyte Lipophagy.

doi: 10.1111/jcmm.70352

Figure Lengend Snippet: FIGURE 5 | SDF-1 inhibits lipophagy in PA-treated hepatocytes via CXCR4, rather than CXCR7. The hepatocytes were divided into normal, PA, PA + SDF-1 neutralising antibody (1 μg for 24 h), PA + AMD3100 (10 μM for 24 h), and PA + ACT-1004-1239 (6 nM for 24 h) groups. (A) LC3, p62 and ATG7 protein levels in hepatocytes were detected by Western blot. (B–D) LC3, p62 and ATG7 relative protein levels were analysed. (E) The co- localization of the autolysosome (red) and the LD (green) in hepatocytes, indicated the induction of lipophagy (yellow). (F) The co-localization of autolysosome and LD was analysed. (G) The LD inside the hepatocytes was visualised by oil red O staining. **p < 0.01, ***p < 0.001 versus normal group. #p < 0.05, ##p < 0.01 versus PA group.

Article Snippet: The mice were assigned into normal, T2DM, T2DM + SDF1 neutralising antibody (MAB310, R&D Systems, USA; 1 mg/kg/day, intrahepatic injection), T2DM + SDF1 neutralising antibody +3- Methyladenine (3- MA; autophagy inhibitor; HY- 19312, MedChemExpress, USA; 30 mg/kg/day, intrahepatic injection), T2DM + metformin (MET; S5958, Selleck, USA; 250 mg/kg/day, once a day from week 4 to week 6 of HFHSD feeding, oral administration) groups.

Techniques: Western Blot, Staining

FIGURE 8 | The role and mechanism of SDF-1 in hepatic IR were displayed. Up-regulated SDF1 binds to its receptor CXCR4 and CXCR7 on he- patocytes following PA treatment. SDF-1/CXCR4 signalling, not SDF-1/CXCR7 signalling, inhibits lipophagy in hepatocytes via activating the phos- phorylation of AKT and mTOR1 to promote PA-induced IR. The blockade of SDF-1/CXCR4/AKT/mTOR signalling-induced lipophagy alleviates IR in PA-treated hepatocytes.

Journal: Journal of cellular and molecular medicine

Article Title: Stromal Cell Derived Factor-1 Promotes Hepatic Insulin Resistance via Inhibiting Hepatocyte Lipophagy.

doi: 10.1111/jcmm.70352

Figure Lengend Snippet: FIGURE 8 | The role and mechanism of SDF-1 in hepatic IR were displayed. Up-regulated SDF1 binds to its receptor CXCR4 and CXCR7 on he- patocytes following PA treatment. SDF-1/CXCR4 signalling, not SDF-1/CXCR7 signalling, inhibits lipophagy in hepatocytes via activating the phos- phorylation of AKT and mTOR1 to promote PA-induced IR. The blockade of SDF-1/CXCR4/AKT/mTOR signalling-induced lipophagy alleviates IR in PA-treated hepatocytes.

Article Snippet: The mice were assigned into normal, T2DM, T2DM + SDF1 neutralising antibody (MAB310, R&D Systems, USA; 1 mg/kg/day, intrahepatic injection), T2DM + SDF1 neutralising antibody +3- Methyladenine (3- MA; autophagy inhibitor; HY- 19312, MedChemExpress, USA; 30 mg/kg/day, intrahepatic injection), T2DM + metformin (MET; S5958, Selleck, USA; 250 mg/kg/day, once a day from week 4 to week 6 of HFHSD feeding, oral administration) groups.

Techniques:

FIGURE 7 | SDF1/CXCR4/AKT/mTOR pathway-inhibited lipophagy promotes PA-induced hepatocyte IR. The hepatocytes were divided into normal, PA, PA + SDF-1 neutralising antibody, PA + SDF-1 neutralising antibody +3-MA (10 mM for 24 h), PA + AMD3100, PA + AMD3100 + 3-MA, PA + MK-2206 2HCl, PA + MK-2206 2HCl + 3-MA, PA + XL388 and PA + XL388 + 3-MA groups. (A) The glucose content of the medium was mea- sured. (B) Glucose consumption by hepatocytes was analysed. **p < 0.01 versus normal group. ##p < 0.01 versus PA group. @p < 0.05 versus PA + SDF- 1 neutralising antibody group. $p < 0.05 versus PA + AMD3100 group. %p < 0.05 versus PA + MK-2206 2HCl group. &p < 0.05 versus PA + XL388 group.

Journal: Journal of cellular and molecular medicine

Article Title: Stromal Cell Derived Factor-1 Promotes Hepatic Insulin Resistance via Inhibiting Hepatocyte Lipophagy.

doi: 10.1111/jcmm.70352

Figure Lengend Snippet: FIGURE 7 | SDF1/CXCR4/AKT/mTOR pathway-inhibited lipophagy promotes PA-induced hepatocyte IR. The hepatocytes were divided into normal, PA, PA + SDF-1 neutralising antibody, PA + SDF-1 neutralising antibody +3-MA (10 mM for 24 h), PA + AMD3100, PA + AMD3100 + 3-MA, PA + MK-2206 2HCl, PA + MK-2206 2HCl + 3-MA, PA + XL388 and PA + XL388 + 3-MA groups. (A) The glucose content of the medium was mea- sured. (B) Glucose consumption by hepatocytes was analysed. **p < 0.01 versus normal group. ##p < 0.01 versus PA group. @p < 0.05 versus PA + SDF- 1 neutralising antibody group. $p < 0.05 versus PA + AMD3100 group. %p < 0.05 versus PA + MK-2206 2HCl group. &p < 0.05 versus PA + XL388 group.

Article Snippet: The mice were assigned into normal, T2DM, T2DM + SDF1 neutralising antibody (MAB310, R&D Systems, USA; 1 mg/kg/day, intrahepatic injection), T2DM + SDF1 neutralising antibody +3- Methyladenine (3- MA; autophagy inhibitor; HY- 19312, MedChemExpress, USA; 30 mg/kg/day, intrahepatic injection), T2DM + metformin (MET; S5958, Selleck, USA; 250 mg/kg/day, once a day from week 4 to week 6 of HFHSD feeding, oral administration) groups.

Techniques: